|
nasdaq:qtrx
|
475075
|
Apr 21st, 2024 12:00AM
|
Quanterix
|
15K
|
422.00
|
Open
|
|
Apr 21st, 2024 12:01AM
|
Apr 21st, 2024 12:01AM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 20th, 2024 12:00AM
|
Quanterix
|
15K
|
422.00
|
Open
|
|
Apr 19th, 2024 11:58PM
|
Apr 20th, 2024 05:32PM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 19th, 2024 12:00AM
|
Quanterix
|
15K
|
423.00
|
Open
|
|
Apr 19th, 2024 12:05AM
|
Apr 19th, 2024 12:05AM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 18th, 2024 12:00AM
|
Quanterix
|
15K
|
423.00
|
Open
|
|
Apr 18th, 2024 12:30AM
|
Apr 18th, 2024 06:52PM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 17th, 2024 12:00AM
|
Quanterix
|
15K
|
422.00
|
Open
|
|
Apr 16th, 2024 11:56PM
|
Apr 17th, 2024 03:19PM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 16th, 2024 12:00AM
|
Quanterix
|
15K
|
422.00
|
Open
|
|
Apr 15th, 2024 11:52PM
|
Apr 16th, 2024 11:35AM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 15th, 2024 12:00AM
|
Quanterix
|
15K
|
422.00
|
Open
|
|
Apr 14th, 2024 11:47PM
|
Apr 15th, 2024 05:16PM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 14th, 2024 12:00AM
|
Quanterix
|
15K
|
422.00
|
Open
|
|
Apr 13th, 2024 11:36PM
|
Apr 13th, 2024 11:36PM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 13th, 2024 12:00AM
|
Quanterix
|
14K
|
422.00
|
Open
|
|
Apr 12th, 2024 11:27PM
|
Apr 13th, 2024 12:01PM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|
|
nasdaq:qtrx
|
475075
|
Apr 12th, 2024 12:00AM
|
Quanterix
|
14K
|
422.00
|
Open
|
|
Apr 11th, 2024 11:34PM
|
Apr 12th, 2024 08:57AM
|
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
|
Open
|
ultrasensitive immunoassay, digital ELISA, proteomics, biomarkers, assays, neurology, oncology, and diagnostics
|
Open
|
900 Middlesex Tpke
|
Billerica
|
Massachusetts
|
US
|
01821
|
|
Quanterix
|
|
|